New combo therapy aims to boost survival for tough esophageal cancers
NCT ID NCT05189730
Summary
This study is testing whether adding an immunotherapy drug (tislelizumab) to chemotherapy helps patients with a specific type of advanced esophageal cancer. The goal is to see if this combination can better control the cancer and help patients live longer. The trial will enroll 80 patients who have already received some initial treatment but are still at high risk of the cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sichuan Cancer Hospital and Research Institute
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.